nach oben

Erschienen in:

01.06.2019 | Case report

Exenatide

Nausea: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

A 60-year-old woman developed nausea during treatment with exenatide for type 2 diabetes. She had type 2 diabetes and a BMI of 37 kg/m². She also had refractory psoriasis from childhood, which required many inpatient admissions and multiple treatments with unspecified systemic agents. She started receiving treatment with exenatide [dosage and route not stated] for type 2 diabetes. Within 2 days, her psoriasis also improved. Subsequently, she developed nausea secondary to treatment with exenatide [exact time to reaction onset not stated]. Thus, exenatide was discontinued after two months of treatment. …

Hogan AE, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: Lessons from obesity, diabetes and psoriasis. Diabetologia 54: 2745-2754, No. 11, Nov 2011. Available from: URL: http://doi.org/10.1007/s00125-011-2232-3 - Ireland

Titel: Exenatide
Nausea: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63721-4

Springer Medizin

Exenatide

Nausea: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Tamoxifen

Heparin

Propylthiouracil

Ketorolac

Prednisone

Levamisole abuse

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Tamoxifen

Heparin

Propylthiouracil

Ketorolac

Prednisone

Levamisole abuse